NCT00421434 - Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Chronic Hepatitis C

Interventions

DRUG

Nitazoxanide

One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.

BIOLOGICAL

Peginterferon alfa-2a

Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.

BIOLOGICAL

Peginterferon alfa-2a

Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.

DRUG

Ribavirin

Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.

DRUG

Ribavirin

Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.

Trial Locations (2)

Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria

Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta

All Listed Sponsors

lead

Romark Laboratories L.C.

INDUSTRY